MM&M

Vertex pain drug passes Phase 3 test, but modest efficacy may hinder uptake

Vertex Pharmaceuticals reported positive results Tuesday for two Phase 3 trials testing the efficacy and safety of pain compound VX-548 compared to either placebo or opioid-based treatment. While both ...
Business Wire

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...
The Manila Times

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster ...
Healio

Neuropathic corneal pain reduced in phase 2 trial of urcosimod

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients who received urcosimod for 12 weeks had a ...